Analysis: Healthcare companies counter investor worries over Wegovy effect

The global market for obesity drugs could reach as much as $100 billion within a decade due to the effectiveness of Novo Nordisk's

"The market is in a shoot-first, ask-questions-later mood when it comes to weight-loss drugs," said Nicholas Anderson, manager of the Thornburg International Growth Fund, which holds shares of Novo Nordisk. "What's less clear on the losers side is who will actually be affected and how long will it take to show up in numbers.

"We expect it will take at least a decade to reach peak penetration of these products in the indicated population," Kenneth Stein, Boston Scientific's global chief medical officer, told investors on Thursday, adding that only a minority of obese American patients will use the drugs.

The weight-loss drugs' cost and uncertainty about whether their use will improve the long-term health of patients and reduce healthcare spending will limit near-term expansion of insurance coverage, said Ann Hynes, a healthcare services analyst at Mizuho Securities.

대한민국 최근 뉴스, 대한민국 헤드 라인

Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.

Analysis-Healthcare companies counter investor worries over Wegovy effectAnalysis-Healthcare companies counter investor worries over Wegovy effect
출처: Investingcom - 🏆 450. / 53 더 많은 것을 읽으십시오 »

Nearly 500 jobs lost following healthcare company closing in OpelikaBaxter is an American Multinational Healthcare company. They primarily focus on products to treat kidney disease, like renal filters for dialysis. Formally known as Gambro, they chose to settle in Opelika back in 2005, investing $165 million into their facility.
출처: wsfa12news - 🏆 338. / 59 더 많은 것을 읽으십시오 »